51 results
8-K
EX-99.1
GLUE
Monte Rosa Therapeutics Inc
9 May 24
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
7:05am
discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has
8-K
EX-99.1
GLUE
Monte Rosa Therapeutics Inc
2 May 24
Departure of Directors or Certain Officers
4:03pm
. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas
8-K
EX-99.1
GLUE
Monte Rosa Therapeutics Inc
14 Mar 24
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:05am
MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated
8-K
EX-99.2
a3knbvdb3rv04asvtgz4
8 Jan 24
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
7:47am
8-K
EX-99.1
vpj2lp6dj
8 Jan 24
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
7:47am
8-K
EX-99.1
b25uf hfs
9 Nov 23
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
7:27am
8-K
EX-99.1
tjlo 1p7pl
26 Oct 23
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
5:01pm
8-K
EX-99.4
t57g b3eiujz
17 Oct 23
Monte Rosa to receive an upfront payment of $50 million and potential future payments exceeding $2 billion
7:55am
8-K
EX-99.2
1miv61pg
17 Oct 23
Monte Rosa to receive an upfront payment of $50 million and potential future payments exceeding $2 billion
7:55am
8-K
EX-99.1
22hffoxy5wk oe
17 Oct 23
Monte Rosa to receive an upfront payment of $50 million and potential future payments exceeding $2 billion
7:55am
PRE 14A
gaj8dhps8o 7ta5oy
12 Apr 23
Preliminary proxy
4:07pm
S-3
EX-1.2
82wygwkwqwlag
1 Jul 22
Shelf registration
5:01pm